South Korea government’s swift response to potential production disruptions of essential medical supplies, such as intravenous therapy (IV) bags, due to naphtha supply instability arising from the Middle East crisis has temporarily eased industry concerns.
On Wednesday, health authorities reported that the Ministry of Food and Drug Safety (MFDS) had conferred with relevant departments, including the Ministry of Health and Welfare and the Ministry of Trade, Industry and Energy. They agreed to expedite approvals for additional manufacturing sites and packaging material changes when necessary to address naphtha supply issues.
This measure aims to minimize production disruptions in a situation where quickly resolving raw material supply problems is challenging. The streamlined process for approving new manufacturing sites and packaging alterations is expected to enhance companies’ ability to adapt swiftly to changing circumstances.
The industry has welcomed this development, particularly as it reflects the government’s quick implementation of regulatory relief measures that the sector had been advocating for.
An industry spokesperson commented that while supply uncertainties persist, the reduced regulatory burden has significantly improved our production flexibility. The ability to expand manufacturing sites to diversify raw material sourcing was a key industry request.
IV bags are manufactured using ethylene-based materials like polyethylene (PE), with naphtha being a crucial component in ethylene production. Notably, about 45% of domestic naphtha demand is met through imports, with 77% of this supply originating from the Middle East.
In recent weeks, major domestic petrochemical firms have reduced naphtha production due to oil supply disruptions. Current estimates suggest that existing inventory levels may only last about two weeks.
Despite these challenges, companies have maintained sufficient inventory levels to avoid significant disruptions in short-term IV bag production.
However, the industry remains vigilant about the potential for a prolonged crisis. Naphtha’s critical role in medical plastics production means that continued supply instability could have far-reaching impacts across various medical fields, including surgical procedures and cancer treatments.
In light of these concerns, the government is preparing contingency plans for potential supply disruptions across all pharmaceutical raw materials, including those used in IV bag production.
An MFDS official stated that they’re working closely with relevant departments to monitor the raw material supply situation and ensure uninterrupted operations in healthcare facilities. The plans include expediting approvals for additional manufacturing sites and packaging changes as needed to support the industry.